Trends in Neurosciences
OpinionAlzheimer's disease – do tauists and baptists finally shake hands?
Section snippets
The ‘amyloid cascade hypothesis’
This was first formulated over a decade ago and centres around the Aβ peptide that is the main component of plaques. This peptide is derived from the membrane bound amyloid precursor protein (APP) which can be processed via two distinct processing pathways: the amyloidogenic pathway that liberates the Aβ peptide and the non-amyloidogenic pathway which precludes the formation of Aβ and instead generates a secreted form of APP, sAPPα [2]. The proponents of the amyloid cascade hypothesis (Fig. 1)
The tau and tangle hypothesis
The persuasiveness of the amyloid cascade hypothesis was so great that it led some to question whether the other main neuropathological lesion, neurofibrillary tangles, was perhaps an epiphenomenon. However, there was a small, but persistent, group that argued that tangles were in fact central to AD. Tangles are comprised of the microtubule associated protein tau, normally expressed in axons but which in AD becomes highly phosphorylated and aggregated into abnormal filaments in the cell body
An abnormality in the wnt signalling pathway might give rise to both pathologies
At this point the baptists and the tauists do indeed shake hands and yet there remains something lacking from the ‘amyloid cascade to tau hypothesis’. One plausible missing factor is vascular disease that, for example, augments tau phosphorylation in some regions early in the disease process (albeit reducing PHF formation in other regions in more severe disease) [46]. Some have proposed that it is the combination of vascular and Alzheimer's disease that is causal in dementia 47, 48. An
Conclusions
Neither the additional factor hypotheses, such as hypoxia, nor the common signalling pathway hypotheses, such as we suggest with wnt, fully resolve the anomaly in the ‘amyloid cascade to tau hypothesis’, namely that mutations in APP give rise to plaques and tangles in man but only plaques in mice. Resolving this anomaly is, however, of considerable importance if therapies are to be developed that are equally efficacious for patients who fit the ‘amyloid cascade to tau hypothesis’ and those who
References (57)
Genes, models and Alzheimer's disease
Trends Genet.
(2001)Targeting small Aβ oligomers: the solution to an Alzheimer's disease conumdrum
Trends. Neurosci.
(2001)Activation of tau protein kinase I glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons
Neurosci. Res.
(1998)Lithium protects cultured neurons against β-amyloid-induced neurodegeneration
FEBS Lett.
(1999)Age related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins
Neuron
(1995)Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations
FEBS Lett.
(1999)Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments
FEBS Lett.
(1999)Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
FEBS Lett.
(1999)Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly
FEBS Lett.
(1998)Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation
FEBS Lett.
(1999)